# "HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"

> **NCT07054359** · NA · NOT_YET_RECRUITING · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 3200 (estimated)

## Conditions studied

- HBV Infection
- Pregnancy

## Interventions

- **DIAGNOSTIC_TEST:** HBsAg RDT Women
- **DRUG:** Treatment by TDF if HBcrAg RDT positive
- **DRUG:** Treatment by TDF
- **OTHER:** Social sciences component
- **DIAGNOSTIC_TEST:** HBsAg RDT Infants

## Key facts

- **NCT ID:** NCT07054359
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11
- **Primary completion:** 2026-11
- **Final completion:** 2028-01
- **Target enrollment:** 3200 (ESTIMATED)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07054359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07054359, ""HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07054359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*